News

Array of light for early disease detection?

May 22, 2012

A special feature in the May 11 issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute’s Virginia G. Piper Center for Personalized Diagnostics.

With the successful completion of the Human Genome Project, research attention is increasingly focusing on proteins. Versatile products produced from genetic templates, proteins are principle actors in both the maintenance of health and the onset of illness. Protein microarrays are a means of bridging the gap between analysis of the nucleotide sequences that make up DNA and the proteome—the universe of proteins built from the amino acids coded for by genes.

Protein microarrays are helping researchers develop early detection methods, particularly for chronic diseases, which account for most of the country’s health care expenditures. Identifying telltale signs of diabetes, coronary artery disease, congestive heart failure and various cancers at an early, pre-symptomatic stage, offers the best prognosis for successful treatment, at dramatically reduced cost.

“Proteins are the machines of biology.  Disease is nearly always a result of protein malfunction, and most drugs are designed to affect protein function.  Protein microarrays enable us to test the biochemical properties of thousands of proteins simultaneously,”  says LaBaer.

While the genome provides the instruction manual for building living systems, proteins are the real molecular workhorses, faithfully carrying out genomic instructions, while also modifying their behavior under myriad environmental influences. Proteins provide structure to cells and tissues, facilitate signaling within and between cells, act as receptors, catalyze enzymatic activity, execute immune functions, and perform countless other biological tasks.

A more thorough understanding of the proteome is therefore vital to diagnostic medicine, particularly for establishing biomarkers—pre-symptomatic indices of early disease states, detectable as protein components in blood. LaBaer’s group is working on discovering biomarkers for a range of deadly illnesses, including, breast, ovarian, lung and oropharyngeal cancers; type I diabetes and assorted infectious pathogens.

Until recently, studying the complexities of proteins, (as opposed to the sequence of four nucleotides making up DNA), has been daunting. A protein microarray usually consists of a library of proteins immobilized on a glass slide or chip in a 2D addressable grid format. Arrays of this sort are made by expressing and painstakingly purifying proteins, then imprinting them onto the slide’s surface.  Once a library of proteins has been splayed out on an array, high-throughput methods can be used to investigate their behavior.

Similar arrays have long been used to study DNA, yielding a steady stream of insights into the genome and in some cases providing rapid and accurate diagnostic tools. Researchers would like to repeat the successes of DNA microarrays with protein microarray technology, though a number of hurdles exist.  Compared with nucleic acids, proteins exhibit enormous structural diversity and complexity. The synthesis, stabilization and purification of proteins are often laborious undertakings. Adequately attaching proteins to the array surface is tricky and subsequent detection of these proteins through binding events is considerably more complex than in the case of nucleic acid arrays.

Protein microarrays can be broken down into two broad categories. With so-called forward phase arrays, one protein sample is screened against multiple reagents. The capture protein—usually an antibody— is first affixed to the slide surface. The immobilized antibody can then be used to capture antigens it recognizes when a test sample is spread over the array. The test sample could be blood, cells, cell lysates, or some other biological specimen. The captured analyte can then be detected directly, using  a fluorescent dye. The technique offers high specificity, but is time consuming.

In reverse phase arrays, the test sample is printed directly on the slide and the array is then detected with a dye-conjugated protein, such as an antibody.  One of the key advantages of the reverse phase microarray is a reduction in the number of antibody probes needed to detect a protein antigen. Examples of both forward and reverse arrays are presented in the current Science review. 

LaBaer’s group works with a novel protein array, designed in their lab. Known as Nucleic Acid Programmable Protein Array or NAPPA, the technique is particularly powerful because it obviates the need to purify proteins prior to their use in a microarray. Instead of using the protein itself, the NAPPA technique spots protein-coding circular pieces of DNA known as plasmids —the blueprints for building proteins—onto slides, bringing the simplicity and low cost of DNA microarray technology into the world of proteomics.

Immediately prior to the use of the array, an in vitro transcription/translation system is applied as a coating on the slide, turning each array into a nanoscale factory for protein production.  Issues of protein stability and purification are avoided, as proteins are synthesized immediately prior to use. (Figure 1 shows a schematic of how NAPPA works.)

“The central concept for NAPPA is to make the proteins ‘fresh’ only moments before testing them and to use the machinery most relevant to the proteins to make them.  Currently we are using human ribosomal machinery to make human proteins,” LaBaer says.

LaBaer’s method currently allows some 2300 genes to be arrayed on a conventional microscope slide. Given the vastness of the human proteome, comprised of more than 30,000 distinct proteins, the technique requires around 10 array slides to fully sample the proteome. Spotting DNA plasmids at higher densities requires new imprinting techniques to avoid chemical cross talk between closely situated array spots. Using advanced piezoelectric-pipetting technology, the group anticipates next generation protein arrays that will improve protein densities per slide by roughly an order of magnitude.

Currently, at the Piper Center’s state of the art facility, some 14,000 human proteins are employed in an array in order to detect antibody targets of disease.  The technique is being used to investigate posttranslational modifications to proteins and for the identification of novel autoantibodies.

Post-translational changes can occur during or after protein synthesis, resulting in modifications to protein residues. Such changes alter physical and chemical properties affecting protein shape and function. The presence of particular autoantibodies may signal presymptomatic recognition of disease antigens, for example those produced by cancerous tumors.  One recent study identified a panel of 28 antigens that can pinpoint early onset breast cancer in blood sera with 80 to 100 percent specificity.

In addition, this research may help speed more effective vaccines to market by identifying immunogenic proteins associated with infectious diseases like cholera, anthrax and Pseudomonas aeruginosa.

“The key to this work,” according top LaBaer, “is to test many patients and many healthy indviduals to determine which responses are specifically found only in the patients.  Most important is to confirm these findings in independent experiments. “

labear_image052212.png

Figure 1: NAPPA in action
First, protein-coding circular fragments of DNA known as plasmids are spotted onto the array surface. These are the blueprints required for the protein library. In the next step, a transcription/translation coating is applied, initiating protein production at the moment the assay is being conducted. Patient blood is then added to the array and the protein-antibody binding events observed.

 

Written by: Richard Harth
Science Writer: Biodesign Institute
richard.harth@asu.edu

Bookmark and Share